Table 1.
Patient demographics
| Characteristic | Total | DCB group | NDB group | p-value |
|---|---|---|---|---|
| Sex | ||||
| Men | 23 (76.7) | 9 (81.8) | 14 (73.7) | > 0.05 |
| Women | 7 (23.3) | 2 (18.2) | 5 (26.3) | |
| Age (yr) | ||||
| ≥ 65 | 17 (56.7) | 4 (36.4) | 13 (68.4) | > 0.05 |
| < 65 | 13 (43.3) | 7 (63.6) | 6 (31.6) | |
| Smoking status | ||||
| Ever | 20 (66.7) | 7 (63.6) | 13 (68.4) | > 0.05 |
| Never | 10 (33.3) | 4 (36.4) | 6 (31.6) | |
| Histology | ||||
| SqCC | 7 (23.3) | 1 (9.1) | 6 (31.6) | > 0.05 |
| Non-SqCC | 23 (76.7) | 10 (90.9) | 13 (68.4) | |
| Agent | ||||
| Nivolumab | 17 (56.7) | 4 (36.4) | 13 (68.4) | > 0.05 |
| Pembrolizumab | 9 (30.0) | 5 (45.5) | 4 (21.1) | |
| Others | 4 (13.3) | 2 (18.2) | 2 (10.5) | |
| IO agent cycle | 7.9 (2–36) | 15.4 (4–36) | 3.5 (2–8) | 0.001* |
| PD-L1 IHC (%) | ||||
| < 1 | 8 (26.7) | 4 (36.4) | 4 (21.1) | > 0.05 |
| 1–49 | 6 (20.0) | 3 (27.3) | 3 (15.8) | |
| ≥ 50 | 16 (53.3) | 4 (36.4) | 12 (63.2) | |
| Genetic alteration | ||||
| TP53 mutant | 9 (30.0) | 2 (22.2) | 7 (36.8) | > 0.05 |
| KRAS mutant | 6 (20.0) | 4 (36.4) | 2 (10.5) | > 0.05 |
| EGFR mutant | 7 (23.3) | 1 (9.1) | 6 (31.6) | > 0.05 |
| TMB (mutation/Mb) | 7.9 (1.76 to 31.72) | 11.2 (2.64 to 31.72) | 6.0 (1.76 to 15.86) | 0.042* |
| Enrichment scorea) (log2FC) | 1.409 ( 0.907 to 2.496) | 0.636 ( 0.196 to 0.946) | 0.337 ( 0.907 to 2.496) | 0.017* |
| Total | 30 (100) | 11 (36.7) | 19 (63.3) | |
Values are presented as number (%) or mean (range). DCB, durable clinical benefit; IHC, immunohistochemistry; IO, immuno-oncology; NDB, no durable benefit; PD-L1, programmed cell death-ligand-1; SqCC, squamous cell carcinoma; TMB, tumor mutational burden.
*
p < 0.05.
a)
Evaluated in only 26 of total 30 specimens due to insufficient RNA quality.